StockData
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Eikon Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.70+0.28 (+3.77%)

Close on Oct 19, 2026

Market cap
$416.90M
P/E (TTM)
–
Dividend yield
–

SEC filings

12 of Eikon Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 23, 2026Oct 23, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 14, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 13, 2026SEC EDGAR
Current report8-KJul 31, 2026Aug 3, 2026SEC EDGAR
Current report8-KJun 5, 2026Jun 10, 2026SEC EDGAR
Current report8-KMay 30, 2026Jun 1, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 11, 2026SEC EDGAR
Current report8-KMay 11, 2026May 11, 2026SEC EDGAR
Current report8-KMar 30, 2026Mar 30, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 30, 2026SEC EDGAR
Current report8-KFeb 6, 2026Feb 6, 2026SEC EDGAR